Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

Short answer: there’s no reliable, up‑to‑the‑minute public list — after the FDA’s enforcement actions many mainstream telehealth companies stopped offering compounded GLP‑1 products, and whether any provider still offers them now depends on the company, the compounding pharmacy they use, and state rules.

What’s realistic and safer

• Major telehealth firms (examples: Ro, Hims & Hers, PlushCare, One Medical, GoodRx Care) now typically evaluate patients and prescribe FDA‑approved GLP‑1 drugs (semaglutide — Ozempic/Wegovy, tirzepatide — Mounjaro/Zepbound) rather than arranging compounded products. That’s generally safer and avoids the legal/quality issues the FDA flagged.
• Some independent telehealth weight‑loss clinics and local compounding pharmacies may still offer compounded GLP‑1 formulations in certain states. Because this market changed rapidly after FDA warnings, availability can shift quickly.

If you’re specifically looking into a compounded GLP‑1, do this first

1. Ask the telehealth provider directly: “Do you prescribe or dispense compounded GLP‑1 products? If so, which compounding pharmacy do you use?”
2. Verify the compounding pharmacy: look for PCAB accreditation (or state board oversight), evidence they follow USP <797>/<800> sterile compounding standards, and ask for lot-specific third‑party sterility/potency testing or a certificate of analysis.
3. Ask about regulatory/legal compliance: is the pharmacy licensed in your state, and does the prescribing practice follow state pharmacy board guidance?
4. Consider alternatives: ask the clinician about FDA‑approved GLP‑1s and whether those are appropriate — these have known dosing, manufacturing controls, and better safety data.
5. Get a clinician‑supervised plan: labs, comorbidity review, and follow‑up reduce risk.

Why I’m not naming a definitive “still offers” list

• Providers changed policies rapidly after FDA action; a service that offered compounded GLP‑1s last month may have stopped (or vice versa).
• Naming a provider as “still offering” could be inaccurate and could encourage use of unvetted products with safety or legal problems.

If you’d like, I can:

• Check the current publicly stated policy for a particular telehealth company you name, or
• Draft the exact questions to send to a telehealth provider or compounding pharmacy to verify safety and legality.